In the Claims

Please cancel claims 6, 16, 18-21, 23-41 and 42 without prejudice to the filing of future continuing applications.

Please substitute the following claims 1, 12, 15 and 17 for the claims 1, 12, 15 and 17 now pending in the above-identified application.

1. (Once Amended) A compound represented by the formula:



(I)

wherein ring A represents benzene ring optionally having a further substituent,

-L- represents -O-, -NR^{3a}-, -S-, -SO-, -SO_2-, -SO_2NR^{3a}-, -$SO_2NHCONR^{3a}$-,

-$SO_2NHC(=NH)NR^{3a}$-, -C(=S)-,



or -$CONR^{3a}$-

wherein R^{3a} and R^{3b} represent independently hydrogen atom, cyano group, hydroxy group, amino group, a C_{1-6} alkyl group or a C_{1-6} alkoxy group,

n represents an integer of 0 to 6,

R is hydrogen atom or a hydrocarbon group optionally having a substituent, and may be different in repetition of n,

R^1 represents a hydrocarbon group optionally having a substituent or a group represented by the formula:



wherein R^7 represents a hydrocarbon group optionally having a substituent,

R^2 represents hydrogen atom, an acyl group, a hydrocarbon group optionally having a substituent or a heterocyclic group optionally having a substituent,

X represents a bond,

k and m are each independently an integer of 0 to 4 and k + m = 4,

or a salt thereof.

12. (Once Amended) A compound selected from the group consisting of

2-[(2-methylphenyl)methyl]-7-[2-[1-[[2-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,

2-[(2-methylphenyl)methyl]-8-[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,

3-[1-(phenylmethyl]-4-piperidinyl]-1-[3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-yl]-1-propanone oxime,

2-[1-[3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-yl]-3-[1-(phenylmethyl)-4-piperidinyl]propylidene]malononitrile,

3-(phenylmethyl)-7-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]sulfanyl]-2,3,4,5-tetrahydro-1H-3-benzazepine,

7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine,

7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine,

7-[[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine,

8-[3-[1-[[3-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]propoxy]-2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepine,

4-[[4-[2-[[2-[(2-methylphenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepine-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-1-benzenecarboximidamide,

8-[2-[1-[[4-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2-[(2-methylphenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepine,

2-(phenylmethyl)-8-[2-[1-[[4-(N,N-diethylaminomethyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,

2-[(2-methylphenyl)methyl]-8-[2-[1-[[3-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,

2-[(2-methylphenyl)methyl]-8-[2-[1-[4-(4,5-dihydro-1H-2-imidazolyl)benzoyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,

2-(phenylmethyl)-7-[[1-[[4-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]methoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,

2-(phenylmethyl)-8-[[1-[[4-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]methoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,

2-(phenylmethyl)-8-[2-[1-[[4-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,

and 2-(phenylmethyl)-8-[2-[1-[(4-dimethylaminophenyl)methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,

or a salt thereof.

15. (Once Amended) A compound represented by the formula:



(I')

wherein ring A represents benzene ring optionally having a further substituent,

-La- represents $-NR^{3a}-$, -S-, -SO-, $-SO_2-$, $-SO_2NR^{3a}-$, $-SO_2NHCONR^{3a}-$, $-SO_2NHC(=NH)NR^{3a}-$, -C(=S)-,



or -$CONR^{3a}$-

wherein R^{3a} and R^{3b} represent independently hydrogen atom, cyano group, hydroxy group, amino group, a C_{1-6} alkyl group or a C_{1-6} alkoxy group,

n represents an integer of 0 to 6,

R is hydrogen atom or a hydrocarbon group optionally having a substituent, and may be different in repetition of n,

R^{1a} represents hydrogen atom or a group represented by the formula:



wherein R^8 represents a hydrocarbon group optionally having a substituent,

R^2 represents hydrogen atom, an acyl group, a hydrocarbon group optionally having a substituent or a heterocyclic group optionally having a substituent,

X represents a bond,

k and m are each independently an integer of 0 to 4 and k + m = 4,

or a salt thereof.

17. (Once Amended) A pharmaceutical composition comprising

a compound represented by the formula:



(I)

wherein ring A represents benzene ring optionally having a further substituent,

-L- represents -O-, $-NR^{3a}-$, -S-, -SO-, $-SO_2-$, $-SO_2NR^{3a}-$, $-SO_2NHCONR^{3a}-$,

$-SO_2NHC(=NH)NR^{3a}-$, -C(=S)-,



or $-CONR^{3a}-$

wherein R^{3a} and R^{3b} represent independently hydrogen atom, cyano group, hydroxy group, amino group, a C_{1-6} alkyl group or a C_{1-6} alkoxy group,

n represents an integer of 0 to 6,

R is hydrogen atom or a hydrocarbon group optionally having a substituent, and may be different in repetition of n,

R^1 represents a hydrocarbon group optionally having a substituent or a group represented by the formula:



wherein R^7 represents a hydrocarbon group optionally having a substituent,

R^2 represents hydrogen atom, an acyl group, a hydrocarbon group optionally having a substituent or a heterocyclic group optionally having a substituent,

X represents a bond,

k and m are each independently an integer of 0 to 4 and k + m = 4,

or a salt thereof or a prodrug thereof

B37 Sub C2

and a pharmacologically acceptable carrier.